畢馬威料香港上半年新股集資額695億元位列全球第三
畢馬威發表報告,預計2019上半年香港IPO市場共錄得74宗新股上市,集資額達695億元,僅次於紐約證券交易所和納斯達克,位列全球新股市場第三。
今年上半年,生命科學行業領跑香港IPO市場,共募集資金達161億元,其中已錄得盈利的企業及新上市機制下尚未取得收入的生物科技企業分別各佔三家。
香港新股市場活躍,錄得超過190宗新股上市申請,為歷史最高水平。畢馬威維持此前預測,預計2019年總集資額規模將超過2,000億元,新股總數達200宗。該行相信,創新科技企業上市仍是下半年香港IPO市場的焦點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.